A Phase 1 interventional study of [14C]-Selpercatinib and Selpercatinib in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it and also to assess the pharmacokinetics (PK), metabolism, and routes and extent of elimination of selpercatinib in healthy male participants. The study will last up to 59 days (Part 1) or 46 days (Part 2) including screening and 7-day safety follow-up.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 165 milligram (mg) of \[14C\]-Selpercatinib (containing approximately 40 µCi).
Drug: [14C]-Selpercatinib
Participants received a single oral dose of 160 mg Selpercatinib followed by single dose of \<100 µg of \[14C\]-Selpercatinib (containing approximately 1 µCi) administered intravenously (IV).
Drug: Selpercatinib · Drug: [14C]-Selpercatinib
Administered as an oral solution
Also known as: LY3527723, LOXO-292
Administered orally
Also known as: LY3527723, LOXO-292
Administered intravenously
Also known as: LY3527723, LOXO-292
Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1)
PK: AUClast of Selpercatinib in plasma
Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: AUClast of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: AUClast of \[14C\] Selpercatinib in plasma and whole blood
Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1)
PK: AUC0-inf of Selpercatinib in plasma
Time frame: PK: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: AUC0-inf of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: AUC0-inf of \[14C\] Selpercatinib in plasma and whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1)
PK: AUC0-24 of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
PK: (AUC0-24) of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: AUC0-24 of \[14C\] Selpercatinib in plasma and whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1)
PK: Cmax of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Cmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: Cmax of \[14C\] Selpercatinib in plasma and whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1)
PK: Tmax of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Tmax of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: Tmax of \[14C\] Selpercatinib in plasma and whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1)
PK: t½ of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: t½ of [14C] Selpercatinib in Plasma and Whole Blood (Part 1) for Total Radioactivity
PK: t½ of \[14C\] Selpercatinib in plasma and whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1)
PK: CL/F of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1)
PK: Vz/F of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1)
PK: AUC0-24 of Selpercatinib in plasma/AUC0-24 of total radioactivity in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose
PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1)
PK: AUC0-24 of total radioactivity in whole blood/AUC0-24 of total radioactivity in whole blood
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose
PK: AUClast of Selpercatinib in Plasma (Part 2)
PK: AUClast of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: AUClast of [14C] Selpercatinib in Plasma (Part 2)
PK: AUClast of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: AUC0-inf of Selpercatinib in Plasma (Part 2)
PK: AUC0-inf of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2)
PK: AUC0-inf of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Cmax of Selpercatinib in Plasma (Part 2)
PK: Cmax of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Cmax of [14C] Selpercatinib in Plasma (Part 2)
PK: Cmax of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Tmax of Selpercatinib in Plasma (Part 2)
PK: Tmax of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Tmax of [14C] Selpercatinib in Plasma (Part 2)
PK: Tmax of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: t½ of Selpercatinib in Plasma (Part 2)
PK: t½ of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: t½ of [14C] Selpercatinib in Plasma (Part 2)
PK: t½ of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: CL/F of Selpercatinib in Plasma (Part 2)
PK: CL/F of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2)
PK: CL of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Vz/F of Selpercatinib in Plasma (Part 2)
PK: Vz/F of Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2)
PK: Vz of \[14C\] Selpercatinib in plasma
Time frame: Pre-dose up to 168 hour post-dose
PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2)
PK: Vss of \[14C\] Selpercatinib in plasma
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2)
Absolute bioavailability was determined by comparing the plasma exposure of LOXO-292 following oral dosing with the plasma exposure of \[14C\]-LOXO-292 following IV dosing.
Time frame: Predose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose
| Milestone | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|---|
| Started | 6 | 6 |
| Received at least 1 dose of study drug | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
PK: AUClast of Selpercatinib in plasma
| hour*nanogram per milliliter (h*ng/mL) | [14C]-Selpercatinib - Part 1 |
|---|---|
| Pharmacokinetics (PK): Area Under the Concentration-time Curve, From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Selpercatinib in Plasma (Part 1) | 24100 ± 20.2 |
PK: AUClast of \[14C\] Selpercatinib in plasma and whole blood
| h*ng equivalents per gram (h*ng Eq/g) | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 21400 ± 21.9 |
| Whole Blood | 11400 ± 38.2 |
PK: AUC0-inf of Selpercatinib in plasma
| hours*nanogram per milliliter (h*ng/mL) | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 Extrapolated to Infinity (AUC0-inf) of Selpercatinib in Plasma (Part 1) | 24200 ± 20.2 |
PK: AUC0-inf of \[14C\] Selpercatinib in plasma and whole blood
| h*ng Eq/g | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 26900 ± 25.8 |
| Whole Blood | 16700 ± 32.8 |
PK: AUC0-24 of Selpercatinib in plasma
| h*ng/mL | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Area Under the Concentration-time Curve, From Time 0 to Hour 24 (AUC0-24) of Selpercatinib in Plasma (Part 1) | 17100 ± 17.7 |
PK: AUC0-24 of \[14C\] Selpercatinib in plasma and whole blood
| h*ng Eq/g | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 21400 ± 21.9 |
| Whole Blood | 12600 ± 23.4 |
PK: Cmax of Selpercatinib in plasma
| ng/mL | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Maximum Observed Concentration (Cmax) of Selpercatinib in Plasma (Part 1) | 1890 ± 22.7 |
PK: Cmax of \[14C\] Selpercatinib in plasma and whole blood
| nanogram equivalents per gram (ng Eq/g) | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 2240 ± 24.6 |
| Whole Blood | 1260 ± 25.8 |
PK: Tmax of Selpercatinib in plasma
| hour (h) | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Time to Reach Cmax (Tmax) of Selpercatinib in Plasma (Part 1) | 1.25 (1.00 to 1.50) |
PK: Tmax of \[14C\] Selpercatinib in plasma and whole blood
| h | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 1.50 (1.00 to 1.50) |
| Whole Blood | 1.50 (1.00 to 2.00) |
PK: t½ of Selpercatinib in plasma
| h | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Apparent First-order Terminal Elimination Half-life (t½) of Selpercatinib in Plasma (Part 1) | 36.5 ± 18.0 |
PK: t½ of \[14C\] Selpercatinib in plasma and whole blood
| h | [14C]-Selpercatinib - Part 1 |
|---|---|
| Plasma | 12.2 ± 2.36 |
| Whole Blood | 10.5 ± 2.79 |
PK: CL/F of Selpercatinib in plasma
| Liter per hour (L/h) | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Selpercatinibin Plasma (Part 1) | 6.83 ± 20.2 |
PK: Vz/F of Selpercatinib in plasma
| Liter (L) | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Apparent Volume of Distribution During the Terminal Phase (Vz/F) of Selpercatinib in Plasma (Part 1) | 323 ± 45.0 |
PK: AUC0-24 of Selpercatinib in plasma/AUC0-24 of total radioactivity in plasma
| Ratio | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Plasma Selpercatinib/Total Radioactivity AUC0-24 Ratio (Part 1) | 0.799 ± 4.4 |
PK: AUC0-24 of total radioactivity in whole blood/AUC0-24 of total radioactivity in whole blood
| Ratio | [14C]-Selpercatinib - Part 1 |
|---|---|
| PK: Blood/Plasma Total Radioactivity AUC0-24 Ratio (Part 1) | 0.590 ± 9.0 |
PK: AUClast of Selpercatinib in plasma
| hour*picogram per mL (h*pg/mL) | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: AUClast of Selpercatinib in Plasma (Part 2) | 20200 ± 26.6 |
PK: AUClast of \[14C\] Selpercatinib in plasma
| h*pg/mL | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: AUClast of [14C] Selpercatinib in Plasma (Part 2) | 1680 ± 30.0 |
PK: AUC0-inf of Selpercatinib in plasma
| h*pg/mL | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: AUC0-inf of Selpercatinib in Plasma (Part 2) | 20300 ± 26.6 |
PK: AUC0-inf of \[14C\] Selpercatinib in plasma
| h*pg/mL | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: AUC0-inf of [14C] Selpercatinib in Plasma (Part 2) | 1720 ± 33.5 |
PK: Cmax of Selpercatinib in plasma
| ng/mL | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Cmax of Selpercatinib in Plasma (Part 2) | 1550 ± 28.0 |
PK: Cmax of \[14C\] Selpercatinib in plasma
| ng/mL | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Cmax of [14C] Selpercatinib in Plasma (Part 2) | 201 ± 30.0 |
PK: Tmax of Selpercatinib in plasma
| h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Tmax of Selpercatinib in Plasma (Part 2) | 1.92 (1.00 to 1.92) |
PK: Tmax of \[14C\] Selpercatinib in plasma
| h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Tmax of [14C] Selpercatinib in Plasma (Part 2) | 0.167 (0.167 to 2.10) |
PK: t½ of Selpercatinib in plasma
| h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: t½ of Selpercatinib in Plasma (Part 2) | 31.5 ± 20.7 |
PK: t½ of \[14C\] Selpercatinib in plasma
| h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: t½ of [14C] Selpercatinib in Plasma (Part 2) | 16.9 ± 7.97 |
PK: CL/F of Selpercatinib in plasma
| L/h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: CL/F of Selpercatinib in Plasma (Part 2) | 7.89 ± 26.6 |
PK: CL of \[14C\] Selpercatinib in plasma
| L/h | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Systemic Clearance (CL) of [14C] Selpercatinib in Plasma (Part 2) | 5.70 ± 33.4 |
PK: Vz/F of Selpercatinib in plasma
| L | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Vz/F of Selpercatinib in Plasma (Part 2) | 307 ± 66.3 |
PK: Vz of \[14C\] Selpercatinib in plasma
| L | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Volume of Distribution During the Terminal Phase (Vz) of [14C] Selpercatinib in Plasma (Part 2) | 127 ± 56.8 |
PK: Vss of \[14C\] Selpercatinib in plasma
| L | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Volume of Distribution at Steady State (Vss) of [14C] Selpercatinib in Plasma (Part 2) | 85.0 ± 21.0 |
Absolute bioavailability was determined by comparing the plasma exposure of LOXO-292 following oral dosing with the plasma exposure of \[14C\]-LOXO-292 following IV dosing.
| Ratio | Selpercatinib and [14C]-Selpercatinib - Part 2 |
|---|---|
| PK: Absolute Bioavailability (F) of Selpercatinib in Plasma (Part 2) | 0.732 ± 13.9 |
Collected over Part 1: Baseline up to Day 29; Part 2: Baseline up to Day 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carbon-14-labelled [14C]-Selpercatinib | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Selpercatinib and [14C]-Selpercatinib | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Event | Carbon-14-labelled [14C]-Selpercatinib | Selpercatinib and [14C]-Selpercatinib |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/6 | 0/6 |
| NauseaGastrointestinal disorders | 2/6 | 0/6 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/6 |
| Dry mouthGastrointestinal disorders | 0/6 | 1/6 |
| VomitingGastrointestinal disorders | 1/6 | 0/6 |
| HeadacheNervous system disorders | 1/6 | 0/6 |
| Hot flushVascular disorders | 1/6 | 0/6 |
All enrolled participants.
| Age, Continuous(years) | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Total |
|---|---|---|---|
| Mean | 35 ± 12.5 | 32 ± 6.2 | 34 ± 9.6 |
| Sex: Female, Male(Participants) | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 6 | 6 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 5 | 5 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 4 | 4 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Carbon-14-labelled [14C]-Selpercatinib - Part 1 | Selpercatinib and [14C]-Selpercatinib - Part 2 | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2018 to primary completion in Sep 2018, 1 month.
Results were first posted in Apr 2025, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib